In October 2017, Mayo Medical Laboratories announced eight new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New Tests
New tests launched in October 2017 by Mayo Medical Laboratories:
- CNS Demyelinating Disease Evaluation, Serum (ID: CDS1)
Test Catalog | Overview PDF
- Dihydropyrimidine Dehydrogenase (DPYD) Genotype (ID: DPYDV)
Test Catalog | Overview PDF - Focused Pharmacogenomics Panel (ID: PGXFP)
Test Catalog | Overview PDF - Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: MOGFS)
Test Catalog | Overview PDF - Neuromuscular Genetic Panels by Next-Generation Sequencing (NGS) (ID: NMPAN)
Test Catalog | Overview PDF - SERPINA1 Gene, Full Gene Analysis (ID: SERPZ)
Test Catalog | Overview PDF - Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping (ID: TPNUV)
Test Catalog | Overview PDF - Warfarin Response Genotype (ID: WARSV)
Test Catalog | Overview PDF
Test Updates
In addition to these new tests, the department also announced several test changes. Click the links below to view test changes announced via Mayo Medical Laboratories:
Dear Alyssa
In our country we are facing a lack of some biological tests. I want to know if it is technicaly and legaly possible to provide you samples drawn from patients here.
Hi Hamza, Mayo Medical Laboratories receives and processes samples from over 70 countries every month. For more information on our international testing capabilities, please email us at mmlglobal@mayo.edu and a representative will follow up with you. Thank you.